HCW Biologics

Historical price data

HCW Biologics is developing a novel class of fusion immunotherapies targeting the interconnected biology of chronic inflammation and aging. Founded by Dr. Hing C. Wong, whose prior discovery led to the FDA-approved immunotherapy Anktiva, the company leverages two proprietary protein engineering platforms to create multi-functional biologics. Its strategy encompasses advancing internal clinical candidates while also commercializing platform-derived reagents for next-generation cell therapy manufacturing, aiming to create value through both therapeutic development and strategic partnerships.

HCW leverages two proprietary protein engineering platforms: the TOBI™ platform, which uses a Tissue-Factor scaffold to build multi-domain cytokine-based immunotherapeutics, and the TRBC platform, which uses a T-Cell Receptor β Chain scaffold to create fusion complexes like immune cell engagers and checkpoint inhibitors.

HCW competes with large biopharma and biotechs in fusion protein therapeutics and with established tools companies in the cell therapy reagent space. Its differentiation lies in its unique scaffold technologies (TOBI, TRBC), the 'inflammaging' focus, and the proven track record of its founder. Success requires demonstrating clear clinical superiority over existing therapies and effective commercial adoption of its platform reagents.